Project Grant R01AI179593

Award Date 6/15/24
Completion Date 5/31/29
Dollars Obligated $2.1M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72202, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the discovery and development of new antifungal therapeutics. The goal is to identify compounds that selectively inhibit the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth in neutral, alkaline, and acidic environments. This research aims to advance the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $558,747 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Texas Tech University Health Sciences Center (TTUHSC) to investigate the connection between calcineurin, amino acid permease, and protein kinase A in the virulence of the fungus Mucor, which causes the life-threatening condition mucormycosis. The project aims to identify key transcription factors regulated by calcineurin, elucidate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,749 to The University of Iowa for a research project titled "Nanobody-Mediated Proteolysis of Aspergillus Fumigatus Transcription Factors In Vitro and In Vivo". The project aims to develop a novel approach to analyze the transcriptional control of virulence in the fungal pathogen Aspergillus...
This $871,154 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to elucidate the molecular mechanisms by which the septin cytoskeleton in the human pathogen Aspergillus fumigatus mediates its response to the antifungal drug caspofungin. The research will be conducted at Virginia Polytechnic Institute & State University and is expected to be...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $170,000.00 to Prokaryotics Incorporated to conduct research focused on developing novel antifungal therapeutics. The research aims to perform structural elucidation of key fungal enzymes involved in glycosylphosphatidylinositol (GPI) biosynthesis, and use those insights to guide the synthesis and evaluation of new...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $262,098 to the University of Wisconsin-Madison to develop and characterize human induced pluripotent stem cell (iPSC)-derived neutrophil therapies against the fungal pathogens Aspergillus fumigatus and Aspergillus flavus. The key goals are to assess the ability of these engineered neutrophils to inhibit the growth...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $940,309 to the Arkansas Children's Research Institute (ACRI) to investigate the role of protein kinase A (PKA) in regulating autophagy pathways that contribute to the pathogenesis of the fungus Aspergillus fumigatus, a leading cause of invasive aspergillosis in immunocompromised patients. The research aims to...
This $494,696 federal Project Grant award, made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance understanding of the translational control mechanisms that regulate the ability of the fungal pathogen Candida albicans to respond to host environmental stresses and undergo morphological transitions critical for virulence. The research will investigate how the C. albicans proteins ASC1 and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $794,375 to The University of Texas Health Science Center at San Antonio (UTHSCSA) for a study on translational control mechanisms regulating Aspergillus fumigatus conidial germination. The research aims to determine the global translational profile of A. fumigatus during conidial germination and identify key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic strategies to treat mucormycosis, a deadly invasive fungal infection. The research aims to examine the role of the host cell hypoxia-response pathway in the pathogenesis of mucormycosis, and to identify and evaluate...

CALCINEURIN CONTROL OVER ASPERGILLUS FUMIGATUS ANTIFUNGAL RESPONSE MECHANISMS - INVASIVE ASPERGILLOSIS DUE TO ASPERGILLUS FUMIGATUS IS A LEADING INFECTIOUS CAUSE OF DEATH IN IMMUNOCOMPROMISED PATIENTS. THE MORTALITY RATE IS A STAGGERING 40-60%, WORSENED BY EMERGING RESISTANCE TO AZOLE ANTIFUNGALS. DESPITE THIS, THERE IS A SIGNIFICANT KNOWLEDGE GAP SURROUNDING THE EFFECTORS GOVERNING A. FUMIGATUS ANTIFUNGAL RESPONSE AND RESISTANCE. WE ESTABLISHED CALCINEURIN (CN) AS A CRITICAL PHOSPHATASE REQUIRED FOR A. FUMIGATUS GROWTH, INVASIVE DISEASE, ANTIFUNGAL RESPONSE AND RESISTANCE. HOWEVER, HOW CN REGULATES THESE PROCESSES IS LARGELY UNDEFINED. WE DEMONSTRATED CN-DEPENDENT TRANSCRIPTIONAL CONTROL OVER ANTIFUNGAL RESPONSE VIA ITS TRANSCRIPTION FACTOR, CRZA. OUR CN PROTEOMIC AND PHOSPHOPROTEOMIC APPROACHES UNCOVERED SEVERAL CELL WALL AND MEMBRANE-RELATED PROTEINS AS POTENTIAL CN EFFECTORS. WE ALSO DEFINED UNIQUE CHANGES IN THE CN PROTEOME IN RESPONSE TO AZOLE AND ECHINOCANDIN ANTIFUNGALS, AND DETECTED CN-DEPENDENT ALTERATIONS IN CELL WALL B-GLUCAN AND MEMBRANE ERGOSTEROL AND LIPID PROFILES. WE WERE ALSO THE FIRST TO CRYSTALLIZE THE FUNGAL CN COMPLEX, AND OUR STRUCTURE-GUIDED INHIBITOR STRATEGIES SHOWED TARGETING CN IS EFFECTIVE IN ANIMAL MODELS. OUR OBJECTIVE IS TO LEVERAGE OUR NOVEL GENETIC, PROTEOMIC AND LIPIDOMIC DATA TO DEFINE CN CONTROL OVER ANTIFUNGAL RESPONSE AND RESISTANCE. OUR CENTRAL HYPOTHESIS IS THAT CN ORCHESTRATES PARALLEL TRANSCRIPTIONAL AND PHOSPHOREGULATORY CONTROL OF KEY EFFECTORS IN CELL WALL AND MEMBRANE ORGANIZATION, THEREBY SPECIFICALLY GOVERNING ANTIFUNGAL RESPONSE AND DRUG RESISTANCE. IN AIM 1, WE WILL IDENTIFY KEY CN EFFECTORS FOR CELL WALL AND MEMBRANE INTEGRITY AND ANTIFUNGAL RESPONSE BY BIMOLECULAR FLUORESCENCE COMPLEMENTATION AND AFFINITY ASSAYS. CN EFFECTOR LOCALIZATION STUDIES IN CN INHIBITED/DELETION BACKGROUNDS WILL CONFIRM CN-DEPENDENCY IN RESPONSE TO ANTIFUNGALS. MOLECULAR MODELING OF CN-EFFECTOR BINDING AND MOLECULAR DYNAMICS SIMULATIONS WILL GUIDE TARGETED MUTATIONS OF PREDICTED CN-BINDING MOTIFS IN EFFECTORS. THESE INTEGRATED APPROACHES WILL ELUCIDATE THE UNKNOWN ROLE PLAYED BY CN IN ANTIFUNGAL RESPONSE THROUGH BINDING AND REGULATION OF KEY EFFECTORS IN CELL WALL AND MEMBRANE SYNTHESIS. IN AIM 2, WE WILL INTERROGATE CN TRANSCRIPTIONAL CONTROL OF EFFECTORS BY EXAMINING EXPRESSION IN THE BACKGROUND OF CN AND CN- DEPENDENT TRANSCRIPTION FACTOR INHIBITION/DELETIONS, INCLUDING MUTATIONS IN PROMOTER CDRE SEQUENCES. WE WILL PERFORM LC-MS/MS OF PHOSPHORYLATION SITES IN CN EFFECTORS IN WILD-TYPE VS. CN-INHIBITED STRAINS UNDER ANTIFUNGAL STRESS. PHOSPHOMUTATIONS IN CN EFFECTORS WILL ASSESS THE REQUIREMENT OF CN-DEPENDENT DEPHOSPHORYLATION AT SPECIFIC RESIDUES FOR FUNCTION IN CELL WALL AND MEMBRANE STRESS RESPONSES. IN AIM 3, WE WILL GENETICALLY CHARACTERIZE CONTRIBUTIONS OF PRIORITIZED CN EFFECTORS TO RESISTANCE IN AZOLE- AND ECHINOCANDIN-RESISTANT STRAINS USING AN ITERATIVE APPROACH OF GENETIC DELETION, TARGETED MUTATIONS, AND MURINE MODEL VALIDATION. WE WILL ALSO BE THE FIRST TO EXAMINE THE EMERGING AZOLE-RESISTANT A. CALIDOUSTUS SPECIES GENETICALLY AND IN ANIMAL MODELS TO FULLY DEFINE CN EFFECTORS' SPECIFIC ROLES IN DRUG RESPONSE AND DISEASE. THIS STUDY WILL, FOR THE FIRST TIME, DEFINE THE MECHANISM OF CN CONTROL OVER ANTIFUNGAL RESPONSE AND RESISTANCE THROUGH CELL WALL AND MEMBRANE EFFECTORS.

Posted 6/14/24, 12:00 AM